Tissue-resident memory T cells (TRM), a recently discovered subtype of CD8+ memory T cells, have shown promise in improving outcomes for patients with NSCLC, oral, or breast cancer treated with anti-PD-1 therapy [98,109,110]. This evidence concerns the gene CD8A and breast carcinoma.